NGM Biopharmaceuticals, Inc.
333 Oyster Point Boulevard
South San Francisco
California
94080
United States
112 articles with NGM Biopharmaceuticals, Inc.
-
NGM Bio Provides Business Highlights and Reports Second Quarter 2022 Financial Results
8/4/2022
NGM Biopharmaceuticals, Inc., a clinical-stage biotechnology company focused on discovering and developing transformative therapeutics for patients, provided business highlights and reported financial results for the quarterly period ended June 30, 2022.
-
Entering the second half of 2022, biopharma and life sciences companies from across the globe strengthen their leadership teams with new additions to the c-suite.
-
NGM Bio Appoints Siobhan Nolan Mangini to President and Chief Financial Officer
6/30/2022
William J. Rieflin to transition from Executive Chairman to Chairman of the Board of Directors.
-
NGM Bio to Host the Final of Four Virtual R&D Events on June 29, 2022
6/23/2022
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it will host the fourth of four virtual R&D events on Wednesday, June 29, 2022, from 11:00 am – 12:30 pm ET.
-
NGM Bio to Participate in Upcoming Investor Conferences - June 02, 2022
6/2/2022
NGM Biopharmaceuticals, Inc. announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the following upcoming investor conferences.
-
NGM Bio to Host the Third of Four Virtual R&D Events on May 31, 2022
5/24/2022
NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced it will host the third of four virtual R&D events on Tuesday, May 31, 2022, from 12:00 pm – 1:15 pm ET.
-
Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio's pediatric methylmalonic acidemia study is back up and running and another look at Roche's TIGIT flop.
-
NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors
5/12/2022
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it has initiated a Phase 1/1b clinical study of NGM438 for the treatment of patients with advanced solid tumors.
-
NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial Results
5/5/2022
NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, provided business highlights and reported financial results for the quarterly period ended March 31, 2022.
-
NGM Bio to Participate in Upcoming Investor Conferences - Apr 20, 2022
4/20/2022
NGM Biopharmaceuticals, Inc. announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the following upcoming virtual investor conferences.
-
NGM Bio to Host the Second of Four Virtual R&D Events on April 27, 2022
4/20/2022
NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced it will host the second of four virtual R&D events on Wednesday, April 27, 2022, from 11:00 am – 12:30 pm ET.
-
NGM Bio to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming Portfolio
4/8/2022
NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, provided additional detail on two late-breaking poster presentations it will give on Wednesday, April 13, 2022, at the American Association for Cancer Research Annual Meeting.
-
NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors
3/31/2022
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it has dosed the first patient in a Phase 1/1b clinical trial of NGM831 for the treatment of patients with advanced solid tumors.
-
NGM Bio to Host the First of Four Virtual R&D Events on March 30, 2022
3/21/2022
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it will host the first of four virtual R&D events on Wednesday, March 30, 2022, from 11:00 am – 12:15 pm ET.
-
NGM Bio Announces Oral and Late-Breaking Poster Presentations Supporting Its Myeloid Reprogramming Portfolio at Upcoming 2022 AACR Annual Meeting
3/8/2022
NGM Biopharmaceuticals, Inc. announced that abstracts related to all three of the company’s myeloid reprogramming and checkpoint inhibition programs have been accepted for presentation at the American Association for Cancer Research Annual Meeting, which will take place April 8 – 13, 2022 at the Ernest N. Morial Convention Center in New Orleans, LA.
-
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results
3/1/2022
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided business highlights and reported financial results for the full year and fourth quarter ending December 31, 2021.
-
NGM Bio to Participate in the Cowen 42nd Annual Health Care Conference
2/28/2022
NGM Biopharmaceuticals, Inc. announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in the Cowen 42nd Annual Health Care Conference as part of the Novel Immuno-oncology Panel and will provide an overview of the company and a business update focusing on NGM Bio’s wholly-owned oncology portfolio on Monday, March 7, at 10:30 am ET.
-
NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
2/7/2022
NGM Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to NGM621, a monoclonal antibody product candidate engineered to potently inhibit complement C3, for the treatment of patients with geographic atrophy.
-
NGM Bio to Participate in Upcoming Investor Conferences - Jan 20, 2022
1/20/2022
NGM Biopharmaceuticals, Inc. announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the following upcoming virtual investor conferences.
-
NGM Bio Outlines 2022 Strategic Priorities Across Its Portfolio of Clinical-Stage Oncology, Retinal and Liver and Metabolic Programs
1/10/2022
After a transformative year in 2021, NGM Bio enters 2022 with a diverse pipeline of seven disclosed programs, including four programs in Phase 2 trials and a wholly-owned oncology portfolio Anticipated milestones in 2022.